ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS;UNIVERSITE PARIS DESCARTES
发明人:
POLAK, MICHEL,CZERNICHOW, PAUL
申请号：
NZ57489207
公开号：
NZ574892A
申请日:
2007.08.01
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Provided is the use of a ATP-sensitive potassium channel ligand selected from sulfamides and glinides, or any combination thereof, for the preparation of a pharmaceutical composition for treating diabetes mellitus and/or a neuropsychological, a muscular and a neurological disorder in a subject having a defective, mutated SUR1 polypeptide, wherein the mutated SUR1 polypeptide exhibits at least one of the following amino acid mutations: L213R, I1424V, C435R, L582V, H1023Y, R1182Q, and R1379C.
